FDA Approves Imfinzi for Stage III NSCLC
- FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing. US Food and Drug Administration Press Announcements. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm597217.htm
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. Antonia, S. et. al. N Engl J Med 2017; 377:1919-1929 DOI: 10.1056/NEJMoa1709937. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa1709937
- US FDA approves Imfinzi for unresectable Stage III non-small cell lung cancer. Astra Zeneca Media Release. 19 February 2018. Available at: https://www.astrazeneca.com/media-centre/press-releases/2018/180202018.html#!